Viking Therapeutics Inc., a biopharmaceutical company in its clinical-stage, is committed to developing innovative therapies for metabolic and endocrine disorders. The company's premier drug candidate, VK2809, is a selective agonist of the thyroid hormone receptor beta (TRß), and is currently undergoing Phase IIb clinical trials to treat biopsy-affirmed non-alcoholic steatohepatitis, as well as NAFLD. Viking Therapeutics is also developing VK5211 - a non-steroidal selective androgen receptor modulator that is orally available and is in its Phase II clinical trials. The drug is intended for patients recovering from non-elective hip fracture surgery. VK0612, another orally available drug candidate for type 2 diabetes, is Phase IIb-ready. The company is also conducting Phase 1 SAD/MAD clinical trials for VK2735, a novel dual agonist of the glucagon-like peptide, and VK0214, an orally-available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. Viking Therapeutics Inc. was founded in 2012 and is headquartered in San Diego, California.